Toll Free: 1-888-928-9744

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 145 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

Summary

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.  The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 5, 9, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Fallopian Tube Cancer, Metastatic Breast Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Gastric Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Metastatic Pancreatic Cancer, Bile Duct Cancer (Cholangiocarcinoma), Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, B-Cell Chronic Lymphocytic Leukemia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Esophageal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Laryngeal Cancer, Leiomyosarcoma, Liver Cancer, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Testicular Cancer, Traumatic Brain Injury, Unspecified and Uveal Melanoma. 

Furthermore, this report also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
- The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview 9 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development 10 Products under Development by Stage of Development 10 Products under Development by Therapy Area 11 Products under Development by Indication 12 Products under Development by Companies 17 Products under Development by Universities/Institutes 26 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment 28 Assessment by Mechanism of Action 28 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development 33 AbbVie Inc 33 American Gene Technologies International Inc 34 AstraZeneca Plc 35 BeiGene Ltd 37 Checkpoint Therapeutics Inc 38 Clovis Oncology Inc 38 Hager Biosciences LLC 39 Ildong Pharmaceutical Co Ltd 39 IMPACT Therapeutics Inc 40 Jeil Pharmaceutical Co Ltd 40 Jiangsu Hengrui Medicine Co Ltd 41 Mitsubishi Tanabe Pharma Corp 41 Nerviano Medical Sciences Srl 42 Shanghai Acebright Pharmaceuticals Group Co Ltd 42 Tasly Pharmaceutical Group Co Ltd 43 Tesaro Inc 43 Teva Pharmaceutical Industries Ltd 44 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles 45 2X-121 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ABT-767 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AG-PD - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AZ-0108 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 AZD-1775 + olaparib - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 AZD-6738 + olaparib - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 BGB-290 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 BGBA-317 + BGB-290 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 cediranib maleate + olaparib - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 CK-102 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 IMP-4297 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 JPI-289 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 MP-124 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 niraparib - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 NMSP-118 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 NMSP-293 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 NOV-1401 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 olaparib - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 R-554 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 rucaparib camsylate - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 SC-10914 - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 SHR-3162 - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Small Molecules to Inhibit PARP1 for Oncology - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 SOMCL-9112 - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 TSL-1502 - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 veliparib ER - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 XZ-120312 - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 YHP-743 - Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products 120 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products 123 Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones 124 Featured News & Press Releases 124 Sep 21, 2017: First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement 124 Sep 15, 2017: TESARO Receives Positive CHMP Opinion for ZEJULA 124 Sep 13, 2017: Clovis Oncology's Rucaparib ARIEL3 Study Data Published in The Lancet 125 Sep 11, 2017: TESARO Summarizes ZEJULA Data Presented at 2017 ESMO Annual Meeting 126 Sep 08, 2017: BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress 129 Sep 07, 2017: Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 130 Aug 30, 2017: Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress 133 Aug 30, 2017: BeiGene Announces Presentations on its PARP inhibitor BGB-290 at the European Society for Medical Oncology 2017 Congress 134 Aug 25, 2017: TESARO Announces Eight Poster Presentations on ZEJULA at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 134 Aug 17, 2017: FDA approves olaparib tablets for maintenance treatment in ovarian cancer 136 Aug 09, 2017: 2X Oncology Announces Validation of Drug Response Predictor for its PARP Inhibitor 2X-121 136 Aug 01, 2017: Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor recently licensed from Eisai 137 Jul 24, 2017: STA Signs Supply Agreement with TESARO 138 Jun 19, 2017: Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival In All Ovarian Cancer Patient Populations Studied In Phase 3 ARIEL3 Maintenance Treatment Trial 139 Jun 05, 2017: BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting 142 Appendix 144 Methodology 144 Coverage 144 Secondary Research 144 Primary Research 144 Expert Panel Validation 144 Contact Us 144 Disclaimer 145
List of Tables
Number of Products under Development by Stage of Development, H2 2017 10 Number of Products under Development by Therapy Areas, H2 2017 11 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15 Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16 Number of Products under Development by Companies, H2 2017 17 Products under Development by Companies, H2 2017 18 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 20 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 21 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 22 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 23 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 24 Products under Development by Companies, H2 2017 (Contd..7), H2 2017 25 Number of Products under Investigation by Universities/Institutes, H2 2017 26 Products under Investigation by Universities/Institutes, H2 2017 27 Number of Products by Stage and Mechanism of Actions, H2 2017 28 Number of Products by Stage and Route of Administration, H2 2017 30 Number of Products by Stage and Molecule Type, H2 2017 32 Pipeline by AbbVie Inc, H2 2017 34 Pipeline by American Gene Technologies International Inc, H2 2017 34 Pipeline by AstraZeneca Plc, H2 2017 36 Pipeline by BeiGene Ltd, H2 2017 37 Pipeline by Checkpoint Therapeutics Inc, H2 2017 38 Pipeline by Clovis Oncology Inc, H2 2017 39 Pipeline by Hager Biosciences LLC, H2 2017 39 Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017 40 Pipeline by IMPACT Therapeutics Inc, H2 2017 40 Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 41 Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 41 Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 42 Pipeline by Nerviano Medical Sciences Srl, H2 2017 42 Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H2 2017 42 Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 43 Pipeline by Tesaro Inc, H2 2017 44 Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 44 Dormant Products, H2 2017 120 Dormant Products, H2 2017 (Contd..1), H2 2017 121 Dormant Products, H2 2017 (Contd..2), H2 2017 122 Discontinued Products, H2 2017 123



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify